Histiocytic Sarcoma – Targeted Therapy: Novel Therapeutic Options? A Series of 4 Cases
Authors:
- Konstantin SchlickKSKonstantin Schlick
- Ariane AigelsreiterAAAriane Aigelsreiter
- Martin PichlerMPMartin Pichler
- Sonja ReitterSRSonja Reitter
- Peter NeumeisterPNPeter Neumeister
- Gerald HoeflerGerald Hoefler
- Christine Beham-SchmidCBChristine Beham-Schmid
- Werner LinkeschWLWerner Linkesch
- 1 January 2012
- journal article
- case report
- Published by S. Karger AG in Onkologie
- Vol. 35 (7-8) , 447-450
Abstract
Histiocytic sarcoma (HS) is a rare but highly aggressive disease. The cancer-specific survival of patients with HS is short and only limited response to conventional chemotherapy or radiation therapy is seen. Some data from single case reports have suggested efficacy for high-dose chemotherapy and autologous/allogeneic stem cell transplantation. We report on 4 cases of HS, and demonstrate that different druggable receptors are expressed on HS. Using immunohistochemistry, we detected the expression of platelet-derived growth factor receptor, vascular endothelial growth factor receptor and epidermal growth factor receptor, which are all well-known targets for novel targeted agents. Based on the marker profile, different novel targeted therapies including imatinib, sorafenib and bevacizumab were applied to the patients. We observed a varying clinical course for each patient. In our case series, we demonstrated that different receptors, which represent potential targets for novel drugs, are expressed on HS tumor cells. For a definitive assessment of the efficacy of these agents a prospective case study of a larger number of patients should be performed.Keywords
This publication has 9 references indexed in Scilit:
- Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven casesLaboratory Investigation, 2011
- Autologous Hematopoietic Stem-Cell Transplantation in Combination With Thalidomide As Treatment for Histiocytic Sarcoma: A Case Report and Review of the LiteratureJournal of Clinical Oncology, 2011
- A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplantLeukemia & Lymphoma, 2011
- A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Leukemia & Lymphoma, 2009
- Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplantAmerican Journal of Hematology, 2007
- Properties of thalidomide and its analogues: Implications for anticancer therapyThe AAPS Journal, 2005
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNature Medicine, 2004
- Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALLLeukemia, 2003
- True Histiocytic Lymphoma (Monocytic Sarcoma)The American Journal of Dermatopathology, 1992